Compare UNIT & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNIT | VCEL |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | N/A | 1997 |
| Metric | UNIT | VCEL |
|---|---|---|
| Price | $7.50 | $38.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $6.58 | ★ $57.50 |
| AVG Volume (30 Days) | ★ 2.8M | 585.5K |
| Earning Date | 02-20-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1036.05 | 236.54 |
| EPS | ★ 8.00 | 0.25 |
| Revenue | ★ $1,610,627,000.00 | $258,716,999.00 |
| Revenue This Year | $97.87 | $17.86 |
| Revenue Next Year | $59.16 | $18.55 |
| P/E Ratio | ★ $0.94 | $156.36 |
| Revenue Growth | ★ 38.94 | 14.05 |
| 52 Week Low | $5.30 | $29.24 |
| 52 Week High | $10.23 | $63.00 |
| Indicator | UNIT | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 64.51 | 53.70 |
| Support Level | $6.61 | $35.33 |
| Resistance Level | $7.59 | $41.65 |
| Average True Range (ATR) | 0.27 | 1.58 |
| MACD | 0.01 | 0.35 |
| Stochastic Oscillator | 92.35 | 52.22 |
Uniti is the product of the August 2025 merger of the firm with Windstream, its former primary customer. The combined firm owns a 217,000 route-mile fiber network that primarily serves enterprise customers. This fiber business generates about 20% of consolidated revenue. Uniti also owns phone networks that reach about 4.5 million households, mostly in less-populated markets in the Southeast. Uniti is rapidly upgrading this network to offer fiber-based broadband services. Its fiber network reaches about 1.8 million locations in its service territory. Residential telecom services account for about a third of total revenue. Small business and wholesale services provided over the legacy phone network account for about 20% of revenue.
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.